The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Zilurgisertib with/without ruxolitinib in patients with anemia due to MF: Phase I/II final results
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the final results of a Phase I/II study (NCT04455841) investigating the activin receptor-like kinase-2 (ALK2) inhibitor zilurgisertib as monotherapy or in combination with ruxolitinib in patients with anemia due to myelofibrosis (MF). Despite its potency in preclinical settings, the agent did not elicit the expected responses in the trial and is not being further developed in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
